Novocure Ltd. is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone44-0-15-3475-6700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$248.07 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date10/31/2019 (Confirmed)
OptionableOptionable
Novocure (NASDAQ:NVCR) Frequently Asked Questions
What is Novocure's stock symbol?
Novocure trades on the NASDAQ under the ticker symbol "NVCR."
How were Novocure's earnings last quarter?
Novocure Ltd (NASDAQ:NVCR) released its quarterly earnings results on Thursday, July, 25th. The medical equipment provider reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.06. The medical equipment provider had revenue of $86.70 million for the quarter, compared to analyst estimates of $78.98 million. Novocure had a negative net margin of 13.84% and a negative return on equity of 31.80%. The firm's revenue was up 41.0% on a year-over-year basis. During the same period last year, the firm earned ($0.17) earnings per share. View Novocure's Earnings History.
When is Novocure's next earnings date?
How can I listen to Novocure's earnings call?
Novocure will be holding an earnings conference call on Thursday, October 31st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What price target have analysts set for NVCR?
6 brokerages have issued twelve-month price objectives for Novocure's stock. Their predictions range from $36.00 to $97.00. On average, they expect Novocure's share price to reach $72.17 in the next year. This suggests a possible upside of 2.8% from the stock's current price. View Analyst Price Targets for Novocure.
What is the consensus analysts' recommendation for Novocure?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novocure.
Has Novocure been receiving favorable news coverage?
News articles about NVCR stock have been trending somewhat positive this week, according to InfoTrie. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Novocure earned a coverage optimism score of 0.9 on InfoTrie's scale. They also gave media headlines about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Novocure.
Are investors shorting Novocure?
Novocure saw a decrease in short interest in the month of September. As of September 30th, there was short interest totalling 4,400,000 shares, a decrease of 7.6% from the August 30th total of 4,760,000 shares. Based on an average daily trading volume, of 854,600 shares, the short-interest ratio is presently 5.1 days. Approximately 5.6% of the company's shares are short sold. View Novocure's Current Options Chain.
Who are some of Novocure's key competitors?
Some companies that are related to Novocure include FRESENIUS SE &/S (FSNUY), ResMed (RMD), Teleflex (TFX), DexCom (DXCM), Insulet (PODD), ABIOMED (ABMD), Hill-Rom (HRC), Haemonetics (HAE), Integra Lifesciences (IART), Penumbra (PEN), Globus Medical (GMED), Tandem Diabetes Care (TNDM), NuVasive (NUVA), ICU Medical (ICUI) and Cantel Medical (CMD).
What other stocks do shareholders of Novocure own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Novocure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners, L.P (CLMT), Two Harbors Investment (TWO), Blackrock Capital Investment (BKCC), Viper Energy Partners (VNOM), Summit Midstream Partners (SMLP), Washington Prime Group (WPG), Roper Technologies (ROP) and Rewalk Robotics (RWLK).
Who are Novocure's key executives?
Novocure's management team includes the folowing people:
- Asaf Danziger, Chief Executive Officer & Director
- Mike Ambrogi, Chief Operating Officer
- Wilco Groenhuysen, CFO & Chief Accounting Officer
- Eilon D. Kirson, Chief Science Officer, Head-Research & Development
- Uri Weinberg, Vice President-Clinical Development
Who are Novocure's major shareholders?
Novocure's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.35%), Peregrine Capital Management LLC (0.15%), Rhumbline Advisers (0.12%), State of New Jersey Common Pension Fund D (0.06%), Essex Investment Management Co. LLC (0.04%) and Tuttle Tactical Management (0.03%). Company insiders that own Novocure stock include Asaf Danziger, Charles G Phillips III, Eilon D Kirson, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen, William F Doyle and Yoram Palti. View Institutional Ownership Trends for Novocure.
Which major investors are selling Novocure stock?
NVCR stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Rhenman & Partners Asset Management AB, Essex Investment Management Co. LLC, Envestnet Asset Management Inc., Crow Point Partners LLC and Rhumbline Advisers. Company insiders that have sold Novocure company stock in the last year include Asaf Danziger, Charles G Phillips III, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen and William F Doyle. View Insider Buying and Selling for Novocure.
Which major investors are buying Novocure stock?
NVCR stock was bought by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Tuttle Tactical Management, Polianta Ltd, Virginia Retirement Systems ET AL, Henry James International Management Inc., Brinker Capital Inc., Alpine Group USVI LLC and Alpine Group USVI LLC. View Insider Buying and Selling for Novocure.
How do I buy shares of Novocure?
Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Novocure's stock price today?
One share of NVCR stock can currently be purchased for approximately $70.21.
How big of a company is Novocure?
Novocure has a market capitalization of $6.89 billion and generates $248.07 million in revenue each year. The medical equipment provider earns $-63,560,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis. View Additional Information About Novocure.
What is Novocure's official website?
How can I contact Novocure?
Novocure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]
MarketBeat Community Rating for Novocure (NASDAQ NVCR)
MarketBeat's community ratings are surveys of what our community members think about Novocure and other stocks. Vote "Outperform" if you believe NVCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
